159150-87-5

Basic information

• Product Name: 4H-1,3-Benzodioxin-8-methanol,6-methyl-2-phenyl-(9CI)
• Synonyms: 4H-1,3-Benzodioxin-8-methanol,6-methyl-2-phenyl-(9CI)
• CAS NO: 159150-87-5
• Molecular Formula: C₁₆H₁₆O₃
• Molecular Weight: 256.29644
• Product Categories: PHENYL
• Mol File: 159150-87-5.mol

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 4H-1,3-Benzodioxin-8-methanol,6-methyl-2-phenyl-(9CI)(CAS DataBase Reference)
• NIST Chemistry Reference: 4H-1,3-Benzodioxin-8-methanol,6-methyl-2-phenyl-(9CI)(159150-87-5)
• EPA Substance Registry System: 4H-1,3-Benzodioxin-8-methanol,6-methyl-2-phenyl-(9CI)(159150-87-5)

Safety Data

• Hazardous Substances Data: 159150-87-5(Hazardous Substances Data)

Upstream product

• 91-04-3 2,6-bis(hydroxymethyl)-4-methylphenol 
• 1125-88-8 benzaldehyde dimethyl acetal 

Downstream Products

• 177034-90-1 2-([bis(2-hydroxybenzyl)amino]methyl)-6-([bis(2-pyridinylmethyl)amino]methyl)-4-methylphenol 
• 159150-89-7 8-(bis(2-pyridylmethyl)aminomethyl)-6-methyl-2-phenyl-2,4-dihydro-1,3-benzodioxine 
• 159150-90-0 2-(N,N-bis(2-pyridinylmethyl)aminomethyl)-6-(hydroxymethyl)-4-methylphenol 
• 195621-22-8 2-(N,N-bis((pyridin-2-yl)methyl)aminomethyl)-6-chloromethyl-4-methylphenol 
• 159150-88-6 8-(bromomethyl)-6-methyl-2-phenyl-2,4-dihydro-1,3-benzodioxine 

Relevant articles and documents

Effect of coordination dissymmetry on the catalytic activity of manganese catalase mimics

Two mixed-valence Mn(II)Mn(III) complexes, [Mn2L1(OAc)2(H2O)]BPh4·2.5H2O and [Mn2L2(OAc)2]·4H2O, obtained with unsymmetrical N4O2

A Novel Phenylchromane Derivative Increases the Rate of Glucose Uptake in L6 Myotubes and Augments Insulin Secretion from Pancreatic Beta-Cells by Activating AMPK

Purpose: A series of novel polycyclic aromatic compounds that augment the rate of glucose uptake in L6 myotubes and increase glucose-stimulated insulin secretion from beta-cells were synthesized. Designing these molecules, we have aimed at the two main pathogenic mechanisms of T2D, deficient insulin secretion and diminished glucose clearance. The ultimate purpose of this work was to create a novel antidiabetic drug candidate with bi-functional mode of action. Methods: All presented compounds were synthesized, and characterized in house. INS-1E cells and L6 myoblasts were used for the experiments. The rate of glucose uptake, mechanism of action, level of insulin secretion and the druggability of the lead compound were studied. Results: The lead compound (6-(1,3-dithiepan-2-yl)-2-phenylchromane), dose- and time-dependently at the low μM range increased the rate of glucose uptake in L6 myotubes and insulin secretion in INS-1E cells. The compound exerted its effects through the activation of the LKB1 (Liver Kinase B1)-AMPK pathway. In vitro metabolic parameters of this lead compound exhibited good druggability. Conclusions: We anticipate that bi-functionality (increased rate of glucose uptake and augmented insulin secretion) will allow the lead compound to be a starting point for the development of a novel class of antidiabetic drugs.

A versatile key synthon for the syntheses of ligands potentially suited for the preparation of μ-phenoxo dimetallic complexes with two non equivalent complexation sites

The synthon S, easily prepared in two steps (65% yield) from 2,6-bis(hydroxymethyl)-4-methylphenol, may allow the syntheses of various dinucleating ligands bearing two chemically different coordination environments. The preparation of the dinucleating lig